ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0005402

lymphoid leukemia

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. lymphoid leukemia. Diseases, record MONDO_0005402. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005402

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
lymphoid leukemia
Open Targets
Open Targets ID
MONDO_0005402
Open Targets
Other names
leukemia, LYMPHOCYTIC, malignant, lymphocytic leukemia, lymphogenous leukaemia, lymphogenous leukemia, lymphoid leukaemia (disease), lymphoid leukemia (disease), subacute lymphoid leukaemia, subacute lymphoid leukemia
Open Targets
Disease Ontology
DOID:1037
Disease Ontology
Disease Ontology
DOID:10747
Disease Ontology
MeSH
D007945
MeSH
NCI Thesaurus
C7539
NCI Thesaurus
Highest stage of its drugs
Approval, for 4 of its 45 drugs, from DailyMed and EMA Human Drugs
Open Targets

Drugs45

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
CYTARABINECHEMBL803Small moleculeApprovalDailyMed766Drugs and targets
MERCAPTOPURINECHEMBL1200751Small moleculeApprovalEMA Human Drugs422Drugs and targets
PONATINIBCHEMBL1171837Small moleculeApprovalEMA Human Drugs211Drugs and targets
DAUNORUBICIN HYDROCHLORIDECHEMBL1563Small moleculeApprovalDailyMed100Drugs and targets
CYCLOPHOSPHAMIDECHEMBL1200796Small moleculePhase 3ClinicalTrials.gov999Drugs and targets
METHOTREXATECHEMBL34259Small moleculePhase 3ClinicalTrials.gov777Drugs and targets
DEXAMETHASONECHEMBL384467Small moleculePhase 3ClinicalTrials.gov555Drugs and targets
DOXORUBICIN HYDROCHLORIDECHEMBL359744Small moleculePhase 3ClinicalTrials.gov333Drugs and targets
VINCRISTINE SULFATECHEMBL501867Small moleculePhase 3ClinicalTrials.gov333Drugs and targets
LEUCOVORIN CALCIUMCHEMBL1201138Small moleculePhase 3ClinicalTrials.gov222Drugs and targets

1 to 10 of 45

See all 45 drugs

Targets145

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
ABL1Bcr/Abl fusion protein5Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitorApprovalhttps://conductscience.org/library/genes/25Drugs and targets
BCRBcr/Abl fusion protein5Bcr/Abl fusion protein inhibitorApprovalhttps://conductscience.org/library/genes/613Drugs and targets
TOP2ADNA topoisomerase 2-alpha4DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitorApprovalhttps://conductscience.org/library/genes/7153Drugs and targets
MS4A1B-lymphocyte antigen CD203B-lymphocyte antigen CD20 binding agentPhase 2https://conductscience.org/library/genes/931Drugs and targets
NR3C1Glucocorticoid receptor3Glucocorticoid receptor agonistPhase 3https://conductscience.org/library/genes/2908Drugs and targets
BTKTyrosine-protein kinase BTK2Tyrosine-protein kinase BTK inhibitorPhase 2https://conductscience.org/library/genes/695Drugs and targets
CD19B-lymphocyte antigen CD192B-lymphocyte antigen CD19 binding agent; B-lymphocyte antigen CD19 cross-linking agentPhase 2https://conductscience.org/library/genes/930Drugs and targets
FKBP1APeptidyl-prolyl cis-trans isomerase FKBP1A2FK506-binding protein 1A inhibitorPhase 2https://conductscience.org/library/genes/2280Drugs and targets
POLA1DNA polymerase (alpha/delta/epsilon)2DNA polymerase (alpha/delta/epsilon) inhibitorApprovalhttps://conductscience.org/library/genes/5422Drugs and targets
POLA2DNA polymerase (alpha/delta/epsilon)2DNA polymerase (alpha/delta/epsilon) inhibitorApprovalhttps://conductscience.org/library/genes/23649Drugs and targets

1 to 10 of 145

See all 145 targets

Trials25

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT01190930Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic LymphomaPhase 39,3502020-06-23
Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma, Ann Arbor Stage II B Lymphoblastic Lymphoma, Childhood B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Lymphoblastic Lymphoma, Down Syndrome, Hypodiploid B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE SULFATEOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT00390793Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.Phase 21072025-02-17
Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, t(9;22)
CYCLOPHOSPHAMIDE, CYTARABINE, DASATINIB ANHYDROUS, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PREDNISONE, VINCRISTINEOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT00792948Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic LeukemiaPhase 2972017-04-26
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Adult L1 Acute Lymphoblastic Leukemia, Adult L2 Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
CYCLOPHOSPHAMIDE, CYTARABINE, DASATINIB ANHYDROUS, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, FILGRASTIM, LEUCOVORIN CALCIUM, METHOTREXATE, METHYLPREDNISOLONE, PREDNISONE, SIROLIMUS, TACROLIMUS ANHYDROUS, VINCRISTINE SULFATE
Open Targets' reading of its recordClinicalTrials.gov
NCT00001575Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid LeukemiaPhase 1/2872015-12-07Hodgkin's Disease, Lymphoma, Non-HodgkinPENTETATE CALCIUM TRISODIUM, YTTRIUM Y-90Its record names the diseaseClinicalTrials.gov
NCT03448393CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesPhase 1542025-06-04
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell, B-Cell Lymphoma, B-Cell Leukemia, Acute Lymphoid Leukemia, B-Non Hodgkin Lymphoma, B-NHL, B-All, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia
CYCLOPHOSPHAMIDE, FLUDARABINE, PENTOSTATINOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT02143414Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic LeukemiaPhase 2532023-01-25
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
BLINATUMOMAB, DASATINIB ANHYDROUS, MERCAPTOPURINE, METHOTREXATE, PREDNISONE, VINCRISTINEOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT03207555Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)Phase 2232025-09-02Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic LeukemiaIBRUTINIBOpen Targets' reading of its recordClinicalTrials.gov
NCT03204188Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaPhase 2152023-04-19
B-Cell Chronic Lymphocytic Leukemia, B-Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Leukemia, Chronic Lymphatic, Leukemia, Chronic Lymphocytic, B-Cell, Leukemia, Lymphocytic, Chronic, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphocytic Leukemia, Chronic, B Cell, Lymphocytic Leukemia, Chronic, B-Cell
FLUDARABINE, IBRUTINIB, PEMBROLIZUMABOpen Targets' reading of its recordClinicalTrials.gov
NCT03572634Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLLPhase 1/232021-02-02Chronic Lymphocytic Leukemia, CLL, SLL, Small Lymphocytic LymphomaDUBERMATINIB, IBRUTINIBOpen Targets' reading of its recordClinicalTrials.gov
NCT04189952Acalabrutinib in Combination With R-ICE For Relapsed or Refractory LymphomaPhase 222022-09-19Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Marginal Zone LymphomaACALABRUTINIB, CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE, RITUXIMABOpen Targets' reading of its recordClinicalTrials.gov

1 to 10 of 25

See all 25 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
TP-0903 Monotherapy (25mg Dose of TP-0903) vs TP-0903 and Ibrutinib Combination Therapy (20 mg Dose of TP-0903): deaths from any cause0 of 10 of 23NCT03572634Trial comparisons
TP-0903 Monotherapy (25mg Dose of TP-0903) vs TP-0903 and Ibrutinib Combination Therapy (20 mg Dose of TP-0903): serious adverse events0 of 12 of 23NCT03572634Trial comparisons

Papers from its trials25

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
42248607DERIVED1PubMed
41671463DERIVED1PubMed
41363770DERIVED1PubMed
40369607DERIVED1PubMed
40315406DERIVED1PubMed
39121442DERIVED1PubMed
39028925DERIVED1PubMed
38968138DERIVED1PubMed
38376944DERIVED1PubMed
37890117DERIVED1PubMed

1 to 10 of 25

See all 25 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005402

GET https://conductscience.org/api/diseases/v1/MONDO_0005402/drugs?page=2

API referenceFor AI assistants